Division of Hematology and Oncology and.
Department of Pathology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Blood. 2015 Jan 1;125(1):40-7. doi: 10.1182/blood-2014-04-516815. Epub 2014 Dec 11.
Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with profound implications on the natural history of this otherwise indolent disease. Recent insights into the genetic and epigenetic basis of transformation have been described, with the recognition of pivotal events governing the initiation and persistence of tumor evolution. Outcomes of patients with transformed lymphoma have historically been poor; however, several studies in the rituximab era suggest that survival may be more favorable than previously recognized. This review highlights our current understanding of transformed follicular lymphoma biology and pathogenesis, current treatment, and future directions.
滤泡性淋巴瘤向侵袭性非霍奇金淋巴瘤的组织学转化是一个关键的生物学事件，对这种原本惰性疾病的自然病程有深远影响。最近已经描述了转化的遗传和表观遗传基础的新见解，认识到控制肿瘤进化起始和持续的关键事件。历史上，转化淋巴瘤患者的预后较差；然而，在利妥昔单抗时代的几项研究表明，生存情况可能比以前认为的更为有利。这篇综述强调了我们目前对转化滤泡性淋巴瘤生物学和发病机制、当前治疗和未来方向的理解。
